Suppr超能文献

四肢及骨盆大异体骨移植的植入情况及临床结果。

Incorporation and clinical results of large allografts of the extremities and pelvis.

作者信息

Aho A J, Ekfors T, Dean P B, Aro H T, Ahonen A, Nikkanen V

机构信息

Department of Surgery, University Central Hospital of Turku, Finland.

出版信息

Clin Orthop Relat Res. 1994 Oct(307):200-13.

PMID:7924034
Abstract

The results of implantation of 37 large deep-frozen allografts with 29 osteoarticular grafts of the extremities and pelvis following the resection of malignant or aggressive benign bone tumors were evaluated at followup (mean, 6 years; range, 2.5-20 years). The patients had excellent or good results in 62% of all cases according to the Mankin-Waber functional rating score, and a corresponding rating of 81% in the Musculoskeletal Tumor Society Score. Benign versus malignant disease rated 83% and 76%, respectively, in the Musculoskeletal Tumor Society Score, and 67% and 46%, respectively, in the Mankin-Waber score. Radiological and nuclear medicine (single-photon emission computed tomography) studies and histological biopsies indicated that the incorporation, perfusion, and replacement with new bone was only partial and of a low degree. Late degenerative cartilage and sclerotic changes occurred in 20 of 29 cases with osteoarticular grafts. The best functional results were achieved with knee osteoarticular allografts (81%-88%) compared with modest results in the proximal humerus (69%) and hemipelvis (57%) according to the Musculoskeletal Tumor Society Score rating. Chemotherapy did not influence the union or infection rate of the allografts. In the 4 cases (11%) with infection, all grafts could be salvaged, but the functional results were only 63% in the Musculoskeletal Tumor Society Score. The overall complication rate was high (57%); graft-related complications occurred in 43%, including fatigue fractures in 27%. There were no cases of nonunion at the host graft junction. Clinical rejection did not occur. These clinical results may be improved in the future by new technology that uses bone substitutes, growth factors, and bone morphogenetic proteins.

摘要

对37例大型深冻同种异体移植进行了评估,这些移植包括29例四肢和骨盆的骨关节移植,是在恶性或侵袭性良性骨肿瘤切除后进行的,随访时间平均为6年(范围为2.5 - 20年)。根据Mankin-Waber功能评分,62%的病例患者结果为优或良,在肌肉骨骼肿瘤学会评分中相应比例为81%。在肌肉骨骼肿瘤学会评分中,良性疾病与恶性疾病的相应比例分别为83%和76%,在Mankin-Waber评分中分别为67%和46%。放射学和核医学(单光子发射计算机断层扫描)研究以及组织活检表明,新骨的整合、灌注和替代仅为部分且程度较低。29例骨关节移植中有20例出现晚期退行性软骨和硬化改变。根据肌肉骨骼肿瘤学会评分,膝关节骨关节同种异体移植取得了最佳功能结果(81% - 88%),相比之下,近端肱骨(69%)和半骨盆(57%)的结果一般。化疗对同种异体移植的愈合或感染率没有影响。在4例(11%)感染病例中,所有移植均得以挽救,但在肌肉骨骼肿瘤学会评分中功能结果仅为63%。总体并发症发生率较高(57%);与移植相关的并发症发生率为43%,其中疲劳骨折发生率为27%。宿主移植连接处未出现不愈合病例。未发生临床排斥反应。未来,通过使用骨替代物、生长因子和骨形态发生蛋白的新技术,这些临床结果可能会得到改善。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验